We are live on ! Find out more

JUNS

Jupiter Neurosciences

JUNS

Market cap $3.31M

2.51 USD

-0.16

5.99%

At close Updated Sep 28, 4:00 PM EDT

1 day

-5.99%

5 days

-13.45%

1 month

-39.95%

3 months

-84.06%

6 months

-89.7%

Year to date

-96.69%

1 year

-98.14%

5 years

-99.39%

10 years

-99.39%

About: Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson's disease program

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering").

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

See News Rankings

Price charts implemented using Lightweight Charts™